| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.
|
J Clin Oncol
|
2004
|
3.40
|
|
2
|
Lower malignancy rates in renal allograft recipients converted to sirolimus-based, calcineurin inhibitor-free immunotherapy: 24-month results from the CONVERT trial.
|
Transplantation
|
2011
|
1.66
|
|
3
|
Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia.
|
Antimicrob Agents Chemother
|
2013
|
1.21
|
|
4
|
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.
|
Antimicrob Agents Chemother
|
2011
|
1.12
|
|
5
|
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
|
Antimicrob Agents Chemother
|
2010
|
1.07
|
|
6
|
Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
|
Clin Ther
|
2012
|
0.91
|
|
7
|
Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.
|
Antimicrob Agents Chemother
|
2011
|
0.88
|
|
8
|
Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.
|
Antimicrob Agents Chemother
|
2007
|
0.88
|
|
9
|
Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia.
|
J Clin Pharmacol
|
2004
|
0.85
|
|
10
|
Absence of a clinically relevant interaction between etanercept and digoxin.
|
J Clin Pharmacol
|
2004
|
0.82
|
|
11
|
Absence of a pharmacokinetic interaction between etanercept and warfarin.
|
J Clin Pharmacol
|
2004
|
0.80
|
|
12
|
Integrated population pharmacokinetics of etanercept in healthy subjects and in patients with rheumatoid arthritis and ankylosing spondylitis.
|
J Clin Pharmacol
|
2010
|
0.77
|
|
13
|
A casting call from industry: reel in and retain appropriate information, release the rest.
|
Pharmacotherapy
|
2002
|
0.75
|
|
14
|
Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
|
PLoS One
|
2017
|
0.75
|
|
15
|
Repeat-dose sirolimus pharmacokinetics and pharmacodynamics in patients with hepatic allografts.
|
Eur J Clin Pharmacol
|
2011
|
0.75
|
|
16
|
The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers.
|
Eur J Clin Pharmacol
|
2012
|
0.75
|